USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
09 May 2023 | 02:15 PM GMT

Pharma Brand Strategies for Driving HCP Engagement and Adoption with Sponsored DTx Solutions

Anchored by:

John Cairns
Global Head of Digital, Oncology Franchise
SANOFI

Participants:

John Cairns Global Head of Digital, Oncology FranchiseSanofi
John Cairns
Global Head of Digital, Oncology FranchiseSanofi
Jo Peddhinti AdvisoryHLTH Community
Jo Peddhinti
AdvisoryHLTH Community
Ashutosh Malhotra Director Digital Health Strategy & PartnersDaiichi Sankyo
Ashutosh Malhotra
Director Digital Health Strategy & PartnersDaiichi Sankyo
Benjamin Alouf Chief Medical OfficerFloreo
Benjamin Alouf
Chief Medical OfficerFloreo
Malin Johansson Vice PresidentNovo Nordisk
Malin Johansson
Vice PresidentNovo Nordisk
Martin Peters Head International Patient ExperienceNovartis
Martin Peters
Head International Patient ExperienceNovartis
Nergis Karacan Deputy Director Global Medical GovernanceBayer
Nergis Karacan
Deputy Director Global Medical GovernanceBayer

About this Meeting

In the aftermath of COVID-19, the patient journey has undergone considerable changes as digital tools and technologies have become increasingly integrated into the journey. HCP adoption is critical for the success of many pharma-sponsored DTx solutions.  

In this roundtable discussion, we will explore how brand/commercial teams across pharma organisations are driving HCP adoption for pharma-sponsored DTx solutions. We will also examine effective ways brand/commercial teams can improve solution awareness and recall among HCPs, evaluate challenges and barriers to HCP adoption, and discuss pharma brand strategies to enable better HCP adoption.  

  • Current approaches, barriers and challenges: How are brand/commercial teams across pharma organisations enabling HCP adoption of pharma-sponsored DTx solutions.  
  • Uncovering HCP preferences and barriers: What do HCPs need when it comes to pharma-sponsored DTx solutions? What are some of the challenges? 
  • Designing and Delivering HCP Communication: How can we design and deliver effective communication around pharma-sponsored DTx? Are traditional sales channels the best choice? 
  • Alternative stakeholders: Often it’s hard to get face time with HCPs. Are there other stakeholders in the clinic/hospital (health navigators, nurses, medical assistants) an effective approach to DTx adoption?
We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.